All articles

Semaglutide Before and After: What Trials Show and What Photos Miss

Reading time:

9 mins

Published on

Updated on

Weight loss

Key Takeaways

  • In the 68-week trial behind Wegovy’s approval for weight management, adults lost an average of 14.9% of their body weight, compared with 2.4% on placebo (1).

  • Results ranged widely, and roughly 1 in 6 people taking Wegovy lost less than 5% of their weight (1).

  • In a two-year Wegovy trial, weight loss leveled off after about week 60 and held near 15% through week 104 (2).

  • These trials tested Wegovy, not compounded semaglutide. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality (3).

Semaglutide before and after results vary a lot from person to person. In the main trial of Wegovy, an FDA-approved prescription semaglutide injection for weight management, the average loss was 14.9% of body weight over 68 weeks (1). Photos show one person. Trials show everyone.

You have probably scrolled past dramatic semaglutide before and after pictures. They can be motivating. They can also set you up for disappointment, because almost nobody posts the photo where the scale barely moved.

This guide walks through what the clinical trials measured, how the timeline tends to unfold, and what a photo cannot show you. Every outcome number here comes from trials of Wegovy (1,2,5). Semaglutide is also sold as Ozempic for type 2 diabetes, and compounding pharmacies prepare it too. Each form has a different regulatory status (3,4).

Key Takeaways

  • In the 68-week trial behind Wegovy’s approval for weight management, adults lost an average of 14.9% of their body weight, compared with 2.4% on placebo (1).

  • Results ranged widely, and roughly 1 in 6 people taking Wegovy lost less than 5% of their weight (1).

  • In a two-year Wegovy trial, weight loss leveled off after about week 60 and held near 15% through week 104 (2).

  • These trials tested Wegovy, not compounded semaglutide. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality (3).

Semaglutide before and after results vary a lot from person to person. In the main trial of Wegovy, an FDA-approved prescription semaglutide injection for weight management, the average loss was 14.9% of body weight over 68 weeks (1). Photos show one person. Trials show everyone.

You have probably scrolled past dramatic semaglutide before and after pictures. They can be motivating. They can also set you up for disappointment, because almost nobody posts the photo where the scale barely moved.

This guide walks through what the clinical trials measured, how the timeline tends to unfold, and what a photo cannot show you. Every outcome number here comes from trials of Wegovy (1,2,5). Semaglutide is also sold as Ozempic for type 2 diabetes, and compounding pharmacies prepare it too. Each form has a different regulatory status (3,4).

The Trial Average Is the Most Honest Before-and-After Picture

The fairest before-and-after comparison comes from a randomized trial, not a social feed. STEP 1 followed 1,961 adults without diabetes for 68 weeks. Each had obesity, or overweight plus a weight-related condition. People taking Wegovy 2.4 mg lost an average of 14.9% of their body weight, while people taking placebo lost 2.4% (1,5).

Both groups also followed a lifestyle program, so the placebo result reflects that program without the medicine (5). Here is how many people in each group crossed common milestones by week 68.

Weight lost by week 68

Wegovy 2.4 mg

Placebo

At least 5%

83.5%

31.1%

At least 10%

66.1%

12%

At least 15%

47.9%

4.8%

To put the average in pounds, picture a starting weight of 220. A 14.9% loss works out to about 33 pounds. That is simple arithmetic on a group average, not a forecast for your body.

The Trial Average Is the Most Honest Before-and-After Picture

The fairest before-and-after comparison comes from a randomized trial, not a social feed. STEP 1 followed 1,961 adults without diabetes for 68 weeks. Each had obesity, or overweight plus a weight-related condition. People taking Wegovy 2.4 mg lost an average of 14.9% of their body weight, while people taking placebo lost 2.4% (1,5).

Both groups also followed a lifestyle program, so the placebo result reflects that program without the medicine (5). Here is how many people in each group crossed common milestones by week 68.

Weight lost by week 68

Wegovy 2.4 mg

Placebo

At least 5%

83.5%

31.1%

At least 10%

66.1%

12%

At least 15%

47.9%

4.8%

To put the average in pounds, picture a starting weight of 220. A 14.9% loss works out to about 33 pounds. That is simple arithmetic on a group average, not a forecast for your body.

About 1 in 6 People Taking Wegovy Lost Less Than 5%

Averages hide the spread. In STEP 1, 83.5% of people taking Wegovy lost at least 5% of their weight, which means roughly 1 in 6 did not reach that mark (1). Fewer than half, 47.9%, lost 15% or more (1).

So a striking photo online may come from the upper end of that range. That does not make it fake. It may just make it unusual.

A trial cannot tell you in advance which group you will land in. Your provider can talk through your health history and what a realistic goal might look like for you. If the scale moves slowly, that is worth a conversation, not a change in dose on your own.

About 1 in 6 People Taking Wegovy Lost Less Than 5%

Averages hide the spread. In STEP 1, 83.5% of people taking Wegovy lost at least 5% of their weight, which means roughly 1 in 6 did not reach that mark (1). Fewer than half, 47.9%, lost 15% or more (1).

So a striking photo online may come from the upper end of that range. That does not make it fake. It may just make it unusual.

A trial cannot tell you in advance which group you will land in. Your provider can talk through your health history and what a realistic goal might look like for you. If the scale moves slowly, that is worth a conversation, not a change in dose on your own.

Most of the Change Shows Up Within the First 60 Weeks

Semaglutide weight loss is front-loaded. In STEP 5, a two-year trial of 304 adults, the authors describe a substantial early drop in weight that plateaued after about week 60. At week 104, the Wegovy group was down 15.2% on average, versus 2.6% on placebo (2).

Dose timing matters, too. The Wegovy label starts low and steps up every four weeks (1).

Time on treatment

What the Wegovy label and trials describe

Weeks 1 to 4

Starting dose of 0.25 mg once weekly (1)

Weeks 5 to 16

Dose rises every 4 weeks: 0.5 mg, 1 mg, then 1.7 mg (1)

Week 17 onward

Maintenance dose of 2.4 mg or 1.7 mg once weekly (1)

Around week 60

Weight loss plateaued in STEP 5 (2)

Week 68

Average loss of 14.9% in STEP 1 (1)

Week 104

Average loss of 15.2% in STEP 5 (2)

These are the FDA-approved Wegovy label doses. Your provider sets your own schedule. Never adjust it on your own.

So a three-month photo and a one-year photo can look very different. For a closer look at the early weeks, see these semaglutide weight loss timelines.

Most of the Change Shows Up Within the First 60 Weeks

Semaglutide weight loss is front-loaded. In STEP 5, a two-year trial of 304 adults, the authors describe a substantial early drop in weight that plateaued after about week 60. At week 104, the Wegovy group was down 15.2% on average, versus 2.6% on placebo (2).

Dose timing matters, too. The Wegovy label starts low and steps up every four weeks (1).

Time on treatment

What the Wegovy label and trials describe

Weeks 1 to 4

Starting dose of 0.25 mg once weekly (1)

Weeks 5 to 16

Dose rises every 4 weeks: 0.5 mg, 1 mg, then 1.7 mg (1)

Week 17 onward

Maintenance dose of 2.4 mg or 1.7 mg once weekly (1)

Around week 60

Weight loss plateaued in STEP 5 (2)

Week 68

Average loss of 14.9% in STEP 1 (1)

Week 104

Average loss of 15.2% in STEP 5 (2)

These are the FDA-approved Wegovy label doses. Your provider sets your own schedule. Never adjust it on your own.

So a three-month photo and a one-year photo can look very different. For a closer look at the early weeks, see these semaglutide weight loss timelines.

Fat Drops Faster Than Lean Mass, but Both Go Down

A photo cannot tell fat from muscle. A body scan can. In a STEP 1 substudy, 140 people had DXA scans, a low-dose X-ray that measures body composition. After 68 weeks on Wegovy, fat mass fell 19.3% and lean mass fell 9.7% (6).

Because fat dropped faster, lean mass made up a bigger share of total body weight at the end, up 3.0 percentage points (6). Visceral fat, the deep belly fat that sits around your organs, fell 27.4% (6).

This was an exploratory analysis in a small group, so treat it as a clue rather than a rule (6).

Want to plan meals with this in mind? Read more about protein on GLP-1 medications.

Your Waist Tells a Story Photos Miss

Your tape measure often tells a clearer story than a camera. In STEP 1, waist circumference fell by an average of 13.5 centimeters, about 5.3 inches, on Wegovy, compared with 4.1 centimeters on placebo (1).

Waist size matters for more than how your jeans fit. The National Heart, Lung, and Blood Institute links a waist over 35 inches in women, or over 40 inches in men, to higher risk of heart disease and type 2 diabetes (7).

The fit of your clothes is another clue a selfie misses. So is the notch you use on your belt. Track those, too.

Before-and-After Pictures Are Chosen, Not Typical

Many before-and-after pictures online show results someone chose to share. Federal advertising rules recognize this problem. Under the FTC’s Endorsement Guides, an ad featuring one person’s result is likely to be read as typical, so the advertiser should clearly disclose what people generally achieve when it is not (8).

That rule covers ads. Social posts and forums have no such filter. When you look at a photo, ask a few questions:

  • How long was this person on treatment?

  • Were they also changing their diet, activity, or other medications?

  • Are the lighting, posture, and clothing the same in both shots?

  • Is the post trying to sell you something?

Your own progress may look less dramatic. That is normal, and the trial ranges above show why (1).

Stopping Treatment Usually Means Regaining Weight

The “after” photo is not the end of the story. One year after STEP 1 participants stopped Wegovy and the lifestyle program, they had regained about two-thirds of the weight they had lost. Their net loss from the start of the trial shrank to 5.6% (5).

Most heart and metabolic improvements also drifted back toward where they started (5). In a separate Wegovy trial, people who switched to placebo after 20 weeks gained 6.9% from that point, while people who stayed on treatment lost another 7.9% (1).

None of this means you can never stop. It means stopping is a decision to make with your provider, with a plan. Learn more about stopping semaglutide.

Semaglutide Comes in Forms With Different FDA Status

Semaglutide products differ in regulatory standing. Wegovy is FDA approved for weight management, Ozempic is FDA approved for type 2 diabetes, and compounded semaglutide is not FDA approved at all (1,3,4).

Product

FDA status

What it is approved or used for

Wegovy injection and tablets

FDA approved

Long-term weight reduction for people 12 and older with obesity and adults with overweight plus a weight-related condition; also heart risk reduction and, in some adults, a liver condition called MASH (1)

Ozempic injection

FDA approved

Type 2 diabetes and related heart and kidney risks; not labeled for weight management (4)

Compounded semaglutide

Not FDA approved

Pharmacy-prepared for one prescription; FDA does not review it for safety, effectiveness, or quality (3)

Compounded semaglutide is accessible through the Mochi Health platform when an affiliated Mochi Medical provider decides it fits your health needs. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. That is why the Wegovy results in this article do not describe compounded products.

The FDA has received reports of dosing errors with compounded injectable semaglutide, including people measuring the wrong amount (3). Follow your provider’s instructions and your vial label exactly.

Wondering if treatment fits you? Check your eligibility.

Side Effects Are Part of the Before and After

Side effects shape how the months in between feel. In Wegovy trials, nausea affected 44% of adults taking the medicine versus 16% on placebo. Diarrhea affected 30% versus 16%, and vomiting and constipation each affected 24% (1).

Wegovy also carries a boxed warning. In rodents, semaglutide causes thyroid C-cell tumors, and it is not known whether this happens in people (1). A provider will discuss this warning with you.

Semaglutide is not for you if you or a family member has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2, called MEN 2 (1). It is also not for anyone who has had a serious allergic reaction to semaglutide or its ingredients (1). Curious how long stomach issues tend to last? See this guide to semaglutide side effects.

How to Track Your Own Progress Without Relying on Photos

If you start treatment, build your own before-and-after record from day one. Use the same conditions every time, and pair photos with measurements a camera cannot fake. Here is a simple routine you can follow.

  1. Take photos in the same spot, with the same light, clothing, and pose, at the same time of day.

  2. Shoot front, side, and back views every four weeks.

  3. Measure your waist just above your hipbones, right after you breathe out, as the NHLBI recommends (7).

  4. Weigh yourself on the same scale, on the same day each week.

  5. Write down how your clothes fit, your energy, and any side effects.

  6. Bring the log to every provider visit and review it together.

A log makes slow weeks easier to read. It also gives your provider something real to work with. For more ideas, see these GLP-1 habits.

The Bottom Line

Semaglutide before and after results range widely. In the main Wegovy trial, the average loss was 14.9% over 68 weeks, and about 1 in 6 people lost less than 5% (1). In a two-year study, most of the loss came before roughly week 60 (2). A single photo online can only show one point in that range.

Compounded semaglutide was not tested in those trials and is not FDA approved (3). If you want to explore treatment, a licensed provider can review your history and goals first. Check your eligibility to get started.

FAQs

How Much Weight Can You Lose on Semaglutide in 3 Months?

Wegovy trials report results at 68 weeks and two years, not at three months, so there is no trial average to quote for that point (1,2). Through week 16, you are still stepping up toward the maintenance dose on the label schedule (1).

Can You Lose Weight in 4 Weeks on Semaglutide?

The first four weeks on Wegovy use the lowest starting dose, 0.25 mg once weekly (1). Results build over many months, and most of the loss in STEP 5 came before about week 60 (2).

How Long Does It Take to Lose 20 Pounds on Semaglutide?

It depends on your starting weight and your response. For someone starting at 220 pounds, 20 pounds is about 9% of body weight. About two-thirds of people taking Wegovy in STEP 1 lost at least 10% by week 68, but the trial did not report when each person passed a pound milestone (1).

Does Semaglutide Change Your Face?

It is one of the most common questions people ask. The trials in this article measured weight, waist size, and body composition, not facial appearance (1,6). For more on this topic, read about Ozempic face.

References

  1. Novo Nordisk. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets: full prescribing information. DailyMed, US National Library of Medicine. Updated 2026. Wegovy label on DailyMed

  2. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091. PMID: 36216945. PMCID: PMC9556320. STEP 5 trial in PMC

  3. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Drug alerts and statements. Content current as of October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

  4. Novo Nordisk. OZEMPIC (semaglutide) injection: full prescribing information. DailyMed, US National Library of Medicine. Updated June 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

  5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. PMID: 35441470. PMCID: PMC9542252. STEP 1 extension in PMC

  6. Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society. 2021;5(Suppl 1):A16-A17. PMCID: PMC8089287. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/

  7. National Heart, Lung, and Blood Institute. Aim for a healthy weight: assessing your weight and health risk. National Institutes of Health. https://www.nhlbi.nih.gov/health/educational/lose_wt/risk.htm

  8. Federal Trade Commission. Guides concerning the use of endorsements and testimonials in advertising: consumer endorsements, 16 CFR 255.2. Code of Federal Regulations. Revised 2023. https://www.law.cornell.edu/cfr/text/16/255.2

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan. Wegovy, Ozempic, and compounded semaglutide require a written prescription from a licensed provider. Speak with a provider to determine if these medications are appropriate for you. Wegovy is FDA-approved to reduce excess body weight and maintain weight reduction long term in eligible patients, and it carries a boxed warning about the risk of thyroid C-cell tumors that a provider will discuss with you. Ozempic is FDA-approved for adults with type 2 diabetes, is not approved for weight management, and also carries a boxed warning about the risk of thyroid C-cell tumors that a provider will discuss with you. Compounded semaglutide is not FDA-approved. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results are not guaranteed and may vary from person to person. All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.

Follow us

All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.

Follow us

All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.

Follow us

All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.

Follow us

All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.